Sujan Shresta

List of Publications by Year
in descending order

79 papers	6,781 citations	71061 41 h-index	62565 80 g-index
82 all docs	82 docs citations	82 times ranked	7090 citing authors

#	Article	IF	Citations
1	Modified mRNA Vaccines Protect against Zika Virus Infection. Cell, 2017, 168, 1114-1125.e10.	13.5	633
2	Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8 ⁺ T cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2046-53.	3.3	524
3	Murine Model for Dengue Virus-Induced Lethal Disease with IncreasedVascular Permeability. Journal of Virology, 2006, 80, 10208-10217.	1.5	316
4	Enhanced Infection of Liver Sinusoidal Endothelial Cells in a Mouse Model of Antibody-Induced Severe Dengue Disease. Cell Host and Microbe, 2010, 7, 128-139.	5.1	311
5	A Protective Role for Dengue Virus-Specific CD8+ T Cells. Journal of Immunology, 2009, 182, 4865-4873.	0.4	305
6	Interferon-Dependent Immunity Is Essential for Resistance to Primary Dengue Virus Infection in Mice, Whereas T- and B-Cell-Dependent Immunity Are Less Critical. Journal of Virology, 2004, 78, 2701-2710.	1.5	287
7	Zika Virus Infects Neural Progenitors in the Adult Mouse Brain and Alters Proliferation. Cell Stem Cell, 2016, 19, 593-598.	5.2	242
8	Mapping and Role of the CD8 + T Cell Response During Primary Zika Virus Infection in Mice. Cell Host and Microbe, 2017, 21, 35-46.	5.1	211
9	Immune Response to Dengue and Zika. Annual Review of Immunology, 2018, 36, 279-308.	9.5	180
10	CD4+ T Cells Are Not Required for the Induction of Dengue Virus-Specific CD8+ T Cell or Antibody Responses but Contribute to Protection after Vaccination. Journal of Immunology, 2010, 185, 5405-5416.	0.4	179
11	Identification of Zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8+ T cells. Nature Microbiology, 2017, 2, 17036.	5.9	167
12	Mouse models of dengue virus infection and disease. Antiviral Research, 2008, 80, 87-93.	1.9	137
13	A Mouse Model of Zika Virus Sexual Transmission and Vaginal Viral Replication. Cell Reports, 2016, 17, 3091-3098.	2.9	137
14	Dengue virus-reactive CD8+ T cells mediate cross-protection against subsequent Zika virus challenge. Nature Communications, 2017, 8, 1459.	5.8	129
15	STAT2 Mediates Innate Immunity to Dengue Virus in the Absence of STAT1 via the Type I Interferon Receptor. PLoS Pathogens, 2011, 7, e1001297.	2.1	124
16	Critical Roles for Both STAT1-Dependent and STAT1-Independent Pathways in the Control of Primary Dengue Virus Infection in Mice. Journal of Immunology, 2005, 175, 3946-3954.	0.4	118
17	A Mouse-Passaged Dengue Virus Strain with Reduced Affinity for Heparan Sulfate Causes Severe Disease in Mice by Establishing Increased Systemic Viral Loads. Journal of Virology, 2008, 82, 8411-8421.	1.5	105
18	Insights into HLA-Restricted T Cell Responses in a Novel Mouse Model of Dengue Virus Infection Point toward New Implications for Vaccine Design. Journal of Immunology, 2011, 187, 4268-4279.	0.4	104

#	Article	IF	Citations
19	Gamma Interferon (IFN-Î³) Receptor Restricts Systemic Dengue Virus Replication and Prevents Paralysis in IFN-Î±/Î² Receptor-Deficient Mice. Journal of Virology, 2012, 86, 12561-12570.	1.5	101
20	The Neurobiology of Zika Virus. Neuron, 2016, 92, 949-958.	3.8	101
21	Immunodominance Changes as a Function of the Infecting Dengue Virus Serotype and Primary versus Secondary Infection. Journal of Virology, 2014, 88, 11383-11394.	1.5	100
22	Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice. Virology, 2004, 319, 262-273.	1.1	99
23	Role of Humoral versus Cellular Responses Induced by a Protective Dengue Vaccine Candidate. PLoS Pathogens, 2013, 9, e1003723.	2.1	94
24	Mouse Models to Study Dengue Virus Immunology and Pathogenesis. Frontiers in Immunology, 2014, 5, 151.	2.2	94
25	Cross-reactive Dengue virus-specific CD8+ T cells protect against Zika virus during pregnancy. Nature Communications, 2018, 9, 3042.	5.8	93
26	CD8+ T Cells Prevent Antigen-Induced Antibody-Dependent Enhancement of Dengue Disease in Mice. Journal of Immunology, 2014, 193, 4117-4124.	0.4	92
27	Protective Role of Cross-Reactive CD8 T Cells Against Dengue Virus Infection. EBioMedicine, 2016, 13, 284-293.	2.7	85
28	An iminosugar with potent inhibition of dengue virus infection in vivo. Antiviral Research, 2013, 98, 35-43.	1.9	83
29	CD8 ⁺ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice. Journal of Virology, 2015, 89, 6494-6505.	1.5	78
30	The Roles of IRF-3 and IRF-7 in Innate Antiviral Immunity against Dengue Virus. Journal of Immunology, 2013, 191, 4194-4201.	0.4	77
31	Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice. Cell Host and Microbe, 2018, 24, 743-750.e5.	5.1	69
32	Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. Scientific Reports, 2015, 5, 12616.	1.6	65
33	Cardif-Mediated Signaling Controls the Initial Innate Response to Dengue Virus In Vivo. Journal of Virology, 2009, 83, 8276-8281.	1.5	63
34	Dengue Virus Vaccine Development. Advances in Virus Research, 2014, 88, 315-372.	0.9	60
35	Zika Virus Protease Cleavage of Host Protein Septin-2 Mediates Mitotic Defects in Neural Progenitors. Neuron, 2019, 101, 1089-1098.e4.	3.8	55
36	Trafficking and Replication Patterns Reveal Splenic Macrophages as Major Targets of Dengue Virus in Mice. Journal of Virology, 2012, 86, 12138-12147.	1.5	54

#	Article	IF	Citations
37	An IRF-3-, IRF-5-, and IRF-7-Independent Pathway of Dengue Viral Resistance Utilizes IRF-1 to Stimulate Type I and II Interferon Responses. Cell Reports, 2017, 21, 1600-1612.	2.9	53
38	Inhibition of endoplasmic reticulum glucosidases is required for inÂvitro and inÂvivo dengue antiviral activity by the iminosugar UV-4. Antiviral Research, 2016, 129, 93-98.	1.9	52
39	Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development. Frontiers in Immunology, 2019, 10, 1316.	2.2	51
40	CD4+ T cells promote humoral immunity and viral control during Zika virus infection. PLoS Pathogens, 2019, 15, e1007474.	2.1	51
41	Dengue Virus Evolution under a Host-Targeted Antiviral. Journal of Virology, 2015, 89, 5592-5601.	1.5	49
42	Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade. JCI Insight, 2021, 6, .	2.3	46
43	Deconvolution of pro- and antiviral genomic responses in Zika virus-infected and bystander macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9172-E9181.	3.3	44
44	Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection. MBio, 2015, 6, e01316-15.	1.8	40
45	Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine?. Current Opinion in Immunology, 2019, 59, 1-8.	2.4	37
46	Targeting Endoplasmic Reticulum Î±-Glucosidase I with a Single-Dose Iminosugar Treatment Protects against Lethal Influenza and Dengue Virus Infections. Journal of Medicinal Chemistry, 2020, 63, 4205-4214.	2.9	37
47	CD4+ T Cells Cross-Reactive with Dengue and Zika Viruses Protect against Zika Virus Infection. Cell Reports, 2020, 31, 107566.	2.9	31
48	Neuroteratogenic Viruses and Lessons for Zika Virus Models. Trends in Microbiology, 2016, 24, 622-636.	3.5	28
49	Spiking Pandemic Potential: Structural and Immunological Aspects of SARS-CoV-2. Trends in Microbiology, 2020, 28, 605-618.	3.5	28
50	Important Advances in the Field of Anti-Dengue Virus Research. Antiviral Chemistry and Chemotherapy, 2011, 21, 105-116.	0.3	26
51	Development of Zika Virus Vaccines. Vaccines, 2018, 6, 7.	2.1	24
52	Role of Complement in Dengue Virus Infection: Protection or Pathogenesis?. MBio, 2012, 3, .	1.8	23
53	A Novel Iminosugar UV-12 with Activity against the Diverse Viruses Influenza and Dengue (Novel) Tj ETQq1 1 0.784314 rgBT /Overloc	1.5	21
54	T Cell Immunity to Zika and Dengue Viral Infections. Journal of Interferon and Cytokine Research, 2017, 37, 475-479.	0.5	20

#	Article	IF	Citations
55	CD8 ⁺ T cells mediate protection against Zika virus induced by an NS3-based vaccine. Science Advances, 2020, 6, .	4.7	20
56	A Zika virus mutation enhances transmission potential and confers escape from protective dengue virus immunity. Cell Reports, 2022, 39, 110655.	2.9	20
57	Mouse models for dengue vaccines and antivirals. Journal of Immunological Methods, 2014, 410, 34-38.	0.6	19
58	Detection of Zika virus in mouse mammary gland and breast milk. PLoS Neglected Tropical Diseases, 2019, 13, e0007080.	1.3	18
59	Tracking the Evolution of Dengue Virus Strains D2S10 and D2S20 by 454 Pyrosequencing. PLoS ONE, 2013, 8, e54220.	1.1	18
60	Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models. Current Opinion in Virology, 2015, 13, 61-66.	2.6	16
61	Synergism between the tyrosine kinase inhibitor sunitinib and Anti-TNF antibody protects against lethal dengue infection. Antiviral Research, 2018, 158, 1-7.	1.9	15
62	Animal models for SARS-Cov2/Covid19 research-A commentary. Biochemical Pharmacology, 2021, 188, 114543.	2.0	14
63	Human Polyclonal Antibodies Prevent Lethal Zika Virus Infection in Mice. Scientific Reports, 2019, 9, 9857.	1.6	12
64	Human FcRn expression and Type I Interferon signaling control Echovirus 11 pathogenesis in mice. PLoS Pathogens, 2021, 17, e1009252.	2.1	12
65	Japanese encephalitis virusâ€“primed CD8+ T cells prevent antibody-dependent enhancement of Zika virus pathogenesis. Journal of Experimental Medicine, 2020, 217, .	4.2	10
66	Investigation of the immunogenicity of Zika glycan loop. Virology Journal, 2020, 17, 43.	1.4	9
67	Novel strategies for discovering inhibitors of Dengue and Zika fever. Expert Opinion on Drug Discovery, 2016, 11, 921-923.	2.5	7
68	Emergence of a Novel Dengue Virus 3 (DENV-3) Genotype-I Coincident with Increased DENV-3 Cases in Yangon, Myanmar between 2017 and 2019. Viruses, 2021, 13, 1152.	1.5	7
69	A longitudinal systems immunologic investigation of acute Zika virus infection in an individual infected while traveling to Caracas, Venezuela. PLoS Neglected Tropical Diseases, 2018, 12, e0007053.	1.3	6
70	Genome-wide approaches to unravelling hostâ€“virus interactions in Dengue and Zika infections. Current Opinion in Virology, 2019, 34, 29-38.	2.6	6
71	The Ability of Zika virus Intravenous Immunoglobulin to Protect From or Enhance Zika Virus Disease. Frontiers in Immunology, 2021, 12, 717425.	2.2	6
72	Repeated exposure to dengue virus elicits robust cross neutralizing antibodies against Zika virus in residents of Northeastern Thailand. Scientific Reports, 2021, 11, 9634.	1.6	5

#	Article	IF	Citations
73	SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement. Antiviral Research, 2021, 195, 105185.	1.9	5
74	ADE-ing and Abetting Zika. Cell Host and Microbe, 2017, 21, 557-558.	5.1	4
75	Whole Genome Sequencing of Dengue Virus Serotype 2 from Two Clinical Isolates and Serological Profile of Dengue in the 2015â€“2016 Nepal Outbreak. American Journal of Tropical Medicine and Hygiene, 2021, 104, 115-120.	0.6	4
76	Animal Models in Dengue. Methods in Molecular Biology, 2014, 1138, 377-390.	0.4	3
77	Protection against dengue virus requires a sustained balance of antibody and T cell responses. Current Opinion in Virology, 2020, 43, 22-27.	2.6	3
78	Acute-phase Serum Cytokine Levels and Correlation with Clinical Outcomes in Children and Adults with Primary and Secondary Dengue Virus Infection in Myanmar between 2017 and 2019. Pathogens, 2022, 11, 558.	1.2	2
79	IMMU-43. ZIKA VIRUS TO TREAT GLIOMA: TURNING COLD TUMORS HOT. Neuro-Oncology, 2020, 22, ii114-ii114.	0.6	0